In conversation with Sanjay Vyas, Executive Vice President, Managing Director India & Global SBU Head-Clinical Trial Supplies & Logistics, Parexel International

Disclaimer: The views expressed in this article are those of the author and do not necessarily reflect the views of the Economic Times – ET Edge Insights, its management, or its members

Sanjay Vyas

In conversation with Sanjay Vyas, Executive Vice President, Managing Director India & Global SBU Head-Clinical Trial Supplies & Logistics, Parexel International

In today’s knowledge-intensive and booming medical field, clinical research is one of the fastest-growing sectors. The industry is growing at an astonishing rate and offers a wide range of employment opportunities for trained professionals.

According to the National Center for Biotechnology Information (NCBI), India has become an increasingly popular country for international pharmaceutical companies to conduct clinical trials. Due to its ability to rapidly recruit patients and reduce clinical trial costs, India is a key strategic imperative for global clinical trials. In developing countries, however, there has been an ethical and scientific concern regarding the globalization of clinical trials

The discussion between Sanjay Vyas, Executive Vice President, Managing Director India & Global SBU Head-Clinical Trial Supplies & Logistics, Parexel International and Dr Meenakshi Vaccher, Assistant Professor, Department of Biochemistry, Institute of Home Economics, University of Delhi, focused on how India could tackle these concerns.

Check out the link to learn more.

Disclaimer: The views expressed in this article are those of the author and do not necessarily reflect the views of the Economic Times – ET Edge Insights, its management, or its members